Triplet Therapeutics, biotech company focused on Huntington’s, quietly shuts down

A biotech company co-founded by venture capital firm Atlas Venture has shut down after running into problems with its lead drug and raising new funding.

Triplet Therapeutics, which was based in Cambridge, Mass., launched in 2019 with a $59 million Series A round from a group of VCs including Atlas, MPM Capital, and Pfizer Ventures.

The goal was to develop drugs for what are known as repeat expansion disorders — genetic diseases that are caused when short chunks of the DNA sequence repeat over and over again in the DNA strand.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In